Optimized treatment of childhood B-lineage acute lymphoblastic leukemia.
10.7499/j.issn.1008-8830.2211041
- Author:
Xiao-Fan ZHU
1
Author Information
1. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin 300020, China.
- Publication Type:Journal Article
- Keywords:
B-lineage acute lymphoblastic leukemia;
Child;
Optimized treatment
- MeSH:
Humans;
Quality of Life;
Precursor Cell Lymphoblastic Leukemia-Lymphoma/drug therapy*;
Prognosis;
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/drug therapy*;
Acute Disease
- From:
Chinese Journal of Contemporary Pediatrics
2023;25(4):344-349
- CountryChina
- Language:Chinese
-
Abstract:
Childhood acute lymphoblastic leukemia (ALL) accounts for about 75% of childhood leukemia cases, and B-lineage acute lymphoblastic leukemia (B-ALL) accounts for more than 80% of childhood ALL cases. Over the past half century, new molecular biological targets discovered by new techniques have been used in precise stratification of disease prognosis, and there has been a gradual increase in the 5-year overall survival rate of childhood ALL. With the increasing attention to long-term quality of life, the treatment of childhood B-ALL has been constantly optimized from induction therapy to the intensity of maintenance therapy, including the treatment of extramedullary leukemia without radiotherapy, which has been tried with successful results. The realization of optimized treatment also benefits from the development of new techniques associated with immunology and molecular biology and the establishment of standardized clinical cohorts and corresponding biobanks. This article summarizes the relevant research on the implementation of precise stratification and the intensity reduction and optimization treatment of B-ALL in recent years, providing reference for clinicians.
